ArticleJournal of neurology2025
Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.Neurology · 2026Article
- Remnant cholesterol and lipid ratios predict the relapse of neuromyelitis optica spectrum disorder.Lipids in health and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis international multicenter retrospective cohort study investigated predictors of relapse, acute attack severity, and six-month disability in patients with AQP4-IgG-positive NMOSD, MOGAD, and double-seronegative demyelinating syndromes.
methodsWe analyzed 238 patients (132 NMOSD, 69 MOGAD, 37 double-seronegative). Clinical features, CSF findings, and timing of acute and maintenance therapies were evaluated as prognostic markers.
resultsIn NMOSD, female sex, delayed initiation of acute therapy, need for plasma exchange, and inflammatory CSF changes were associated with greater disability at the nadir of the first attack. Older age and longer disease duration predicted higher six-month disability, while oral corticosteroid tapering was protective. Higher EDSS at onset was associated with poorer six-month recovery. No factor significantly predicted relapse. In MOGAD, optic neuritis at onset and early IVMP were associated with lower six-month disability and higher recovery rates, whereas post-IVMP corticosteroid tapering correlated with higher six-month disability. CSF pleocytosis correlated with favorable recovery. Higher EDSS at onset predicted worse six-month outcomes. Early initiation of maintenance therapy reduced relapse risk although overall use versus none was not statistically conclusive. In double-seronegative patients, short steroid tapers, elevated CSF glucose, antecedent infections or vaccinations, and delayed maintenance therapy were associated with worse six-month recovery though no independent predictors were confirmed in multivariable analyses.
conclusionsPrognostic factors differed across subgroups. NMOSD outcomes were influenced by age, disease duration, and steroid tapering; MOGAD outcomes by onset phenotype, early therapy, and maintenance treatment; and seronegative outcomes by treatment timing and immune antecedents. These findings emphasize early, tailored therapy and distinct subgroup-specific prognostic considerations in antibody-mediated and seronegative demyelinating disorders.
Indexed as
Identifiers
41055773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.